Document is current
Any future updates will be listed below
-
Authors
Nielsen, Aleksandra Weronika
Manoochehri, Hafez Eslami
Zhong, Hua
Panwar, Vandana
Jarmale, Vipul
Jasti, Jay
Nourani, Mehrdad
Rakheja, Dinesh
Brugarolas, James
Kapur, Payal
Rajaram, Satwik
-
Funding
Funding for this research was provided by:
The Cancer Prevention and Research Institute of Texas (RP210041, RP220294, RP220294, RP220294, RP220294, RP220294)
Lyda Hill Department of Bioinformatics
Specialized Program in Research Excellence in Kidney Cancer (P50 CA196516, P50 CA196516)
- License Information
-
More Information
Article History
Received: 21 February 2025
Accepted: 26 June 2025
First Online: 19 September 2025
Declarations
:
: Analysis of UTSW samples was conducted with approval by our Institutional (UT Southwestern Medical Center and Parkland Hospital, Dallas) Review Board (IRB: STU 022015–015 and STU 012011–190) and conducted in accordance with the principles of the Declaration of Helsinki. Specifically: (1) For the WSI-1 and WSI-2 cohorts, data was obtained from archival pathology specimens and clinical records under IRB protocols that permitted use of de-identified materials without written informed consent due to the retrospective nature of the research and minimal risk to participants. (2) Three patients from the WSI-1 cohort (Patients A, B, and C) underwent additional genomic analysis. Of these, Patients B and C provided written informed consent for public data sharing, and theirsequencing data was deposited accordingly. Other cohorts used are publicly available.
: Not applicable.
: The authors declare no competing interests.
